Inhibition of 11β‐Hydroxysteroid dehydrogenase‐1 with AZD4017 in patients with nonalcoholic steatohepatitis or nonalcoholic fatty liver disease: A randomized, double‐blind, placebo‐controlled, phase II study

AIM: To evaluate whether short‐term treatment with a selective 11β‐Hydroxysteroid dehydrogenase‐1 (11β‐HSD1) inhibitor, AZD4017, would block hepatic cortisol production and thereby decrease hepatic fat in patients with nonalcoholic fatty liver disease (NAFLD)/nonalcoholic steatohepatitis (NASH), wit...

Descripción completa

Detalles Bibliográficos
Autores principales: Yadav, Yogesh, Dunagan, Kelly, Khot, Rachita, Venkatesh, Sudhakar K., Port, John, Galderisi, Alfonso, Cobelli, Claudio, Wegner, Craig, Basu, Ananda, Carter, Rickey, Basu, Rita
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9135169/
https://www.ncbi.nlm.nih.gov/pubmed/35014156
http://dx.doi.org/10.1111/dom.14646

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9135169/
https://www.ncbi.nlm.nih.gov/pubmed/35014156
http://dx.doi.org/10.1111/dom.14646

Ejemplares similares